Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling

Macdonald, R Loch; Higashida, Randall T; Keller, Emanuela; Mayer, Stephan A; Molyneux, Andy; Raabe, Andreas; Vajkoczy, Peter; Wanke, Isabel; Bach, Doris; Frey, Aline; Nowbakht, Pegah; Roux, Sébastien; Kassell, Neal (2012). Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke, 43(6), pp. 1463-9. Baltimore, Md.: Lippincott Williams & Wilkins 10.1161/STROKEAHA.111.648980

Full text not available from this repository. (Request a copy)

Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by endovascular coiling.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurosurgery

UniBE Contributor:

Raabe, Andreas

ISSN:

0039-2499

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:37

Last Modified:

17 Mar 2015 21:28

Publisher DOI:

10.1161/STROKEAHA.111.648980

PubMed ID:

22403047

Web of Science ID:

000304523800011

URI:

https://boris.unibe.ch/id/eprint/14832 (FactScience: 221966)

Actions (login required)

Edit item Edit item
Provide Feedback